Understanding the factors that lead to the therapeutic success of adoptive cell therapies using tumor-infiltrating lymphocytes (TIL-ACT) will improve current treatment protocols. In this issue of Immunity, Chiffelle et al. comprehensively compare the dynamics of CD8⁺ T cell clonotypes during the course of ACT between responding and non-responding patients.

中文翻译：

---

TIL 结束：在过继细胞治疗期间跟踪 T 细胞克隆型动力学


了解导致使用肿瘤浸润淋巴细胞 （TIL-ACT） 的过继细胞疗法治疗成功的因素将改进当前的治疗方案。在本期 Immunity 中，Chiffelle 等人全面比较了 ACT 过程中有反应和无反应患者的 CD8⁺ T 细胞克隆型的动力学。